Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGynecological OncologyradiotherapyDiseaseCervical CancerSubgroupICD10C53.-MeSHUterine Cervical NeoplasmsSequenceBEATcc: ATEZ1200/BEVA15/PACL175/CISP50, Cervical Ca (PID2658) -|- ATEZ1200/BEVA15, Maint. (PID2659)BEATcc: ATEZ1200/BEVA15/PACL175/CRBP5, Cervical Ca (PID2657) -|- ATEZ1200/BEVA15, maint. (PID2659)BEVA15/PACL175/CRBP5, Cervical Ca (PID2605) -|- BEVA15, maint. (PID2611)ENGOT-cx11/ GOG-3047/KEYNOTE-A18: PEMB200/CISP40/Radiation, Cervical Ca, C1-2 (PID2654) -|- PEMB200, C3-5 (PID2655) -|- PEMB400, C6-21 (PID2656)INTERLACE: PACL80/CRBP2, Cervical Ca, Ind. (PID2748) -|- CISP40/Radiation, Var. 1 (PID2749)KEYNOTE-826: PEMB200/PACL175/CISP50, Cervical Ca, C1-6 (PID1900) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CISP50/BEVA15, Cervical Ca, C1-6 (PID1891) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).KEYNOTE-826: PEMB200/PACL175/CRBP5, Cervical Ca, C1-6 (PID1892) -|- PEMB200, C7+ (PID1893)KEYNOTE-826: PEMB200/PACL175/CRBP5/BEVA15, Cervical Ca, C1-6 (PID1890) -|- PEMB200/BEVA15, C7+ (PID2251) or PEMB200, C7+ (PID1893).PACL135/CISP30/Radiation, Cervical Ca (PID1990)ChemotherapyChemo-substanceAtezolizumabBevacizumabCarboplatinCemiplimabCisplatinGemcitabinePaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceAtezolizumabBevacizumabCarboplatinCemiplimabCisplatinGemcitabinePaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceAtezolizumabBevacizumabCarboplatinCemiplimabCisplatinGemcitabinePaclitaxelPembrolizumabTisotumab vedotinTopotecanChemo-substanceAtezolizumabBevacizumabCarboplatinCemiplimabCisplatinGemcitabinePaclitaxelPembrolizumabTisotumab vedotinTopotecanNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineDexamethasoneDimetindenFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%NaphazolinePegfilgrastimPotassium chlorideNo. Substances123456789Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseConsolidationInductionMaintenanceTherapy intentioncurativepalliativeRisksAbdominal PainAdrenal InsufficiencyAllergic ReactionAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaAstheniaBleedingCardiotoxicityColitisConjunctivitisConstipationCystitisDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaFistulasGastrointestinal ToxicityHand-Foot SyndromeHemorrhageHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypokalemiaHypophysitisHypothyroidismIncrease AminotransferasesInfectionsLeukopeniaMyalgiasNeuropathyNeutropeniaOral MucositisPainPneumonitisProteinuriaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlThromboembolic EventVisual DisturbancesVomiting only studiesPublicationAuthorChung HCColombo NHong DSHuang HKatanyoo KKitagawa RLong HLorusso DMcCormack M Oaknin A Pattaranutaporn PSehouli JTewari KSDiseasefortgeschrittenes oder rezidiviertes Zervixkarzinom, Stadium IVb, ECOG 0-2fortgeschrittenes Zervix-Ca, nach Vorbehandlung, ECOG 0-1fortgeschrittenes Zervixkarzinom, Stadium IIb-IVaLokal fortgeschrittenes oder metastasierten Zervixkarzinom, ohne Möglichkeit einer kurativen Therapie, Erstlinie, ECOG 0-1Metastasierendes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes, wiederkehrendes oder persistierendes Zervix Ca, ECOG/GOG 0-1metastasiertes oder wiederkehrendes Zervixkarzinom, Platin-Vortherapie, keine Taxan-Vortherapie, ECOG 0-2Zervix-Ca, metastasiert oder rezidiviert, Progress nach platinhaltiger Therapie, ECOG 0-1Zervix-Ca lokal fortgeschritten, nicht operabel oder metastasiert, nach platinhaltiger Therapie, ECOG 0-1Zervix Ca, FIGO IB1, IB2, IIA1, IIA2, nach Hysterektomie und pelviner LymphadenektomieZervixkarzinom (Plattenepithel-), FIGO IIIB, keine Vortherapie, ECOG 0-2Zervixkarzinom, FIGO 2008 Stadium IB1 mit N+, oder Stadium IB2, IIA, IIB, IIIB, IVAZervixkarzinom, FIGO Stadium IB2-IIB oder IBI + Risikofaktoren, nach radikaler HysterektomieZervixkarzinom, lokal fortgeschritten, Hochrisiko (FIGO 2014 IB2–IIB, N+, oder III–IVA), ECOG 0-1Zervixkarzinom, metastasiert oder rezidiviert, inoperabel, ECOG 0-1Zervixkarzinom, rezidiviert oder metastasiert, ECOG 0-1OriginCollaborative Innovation Center for Cancer Medicine, Guangzhou, China, STARS trialDepartment of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, ThailandDivision of Radiation Oncology, Mahidol University, Bangkok, 10700, ThailandFondazione Policlinico Universitario A Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy, ENGOT-cx11/ GOG-3047/KEYNOTE-A18 trialMayo Clinic College of Medicine, Rochester, MN, GOG StudyNOGGO-AGONRG Oncology-Gynecologic Oncology Group (GOG240)NTT Medical Center Tokyo, Trial JCOG0505The University of Texas MD Anderson Cancer Center, Texas, USA, innovaTV 201 studyUniversity College Hospital NHS Trust, London, UK, GCIG INTERLACE trialUniversity of California, Irvine, CA, EMPOWER- Cervical 1/GOG-3016/ENGOT-cx9University of Milan-Bicocca, European Institute of Oncology IRCCS, Italy, KEYNOTE-826 trialUniversity of Milan–Bicocca and European Institute of Oncology IRCCS, MilanVall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, BEATcc trialYonsei Cancer Center, Yonsei University College of Medicine, Seoul, KEYNOTE 158Protocols in Revision 28 protocols foundAtezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2657 V1.0)Atezolizumab 1200 / Bevazicumab 15 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer (PID2658 V1.0)Atezolizumab 1200 / Bevazicumab 15, Cervical Cancer, maintenance (PID2659 V1.0)Bevacizumab 15 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID2605 V1.0)Bevacizumab 15, Cervical Cancer, maintenance (PID2611 V1.0)Carboplatin 2 / Radiation, Cervical Cancer (PID1939 V1.0)Cemiplimab 350, Cervical Cancer (PID1981 V1.0)Cisplatin 40 / Radiation, Cervical Cancer Adjuvant (PID540 V1.2)Cisplatin 40 / Radiation, Cervical Cancer, Variant 1 (PID2749 V1.0)Gemcitabine 300 / Radiation, Cervical Cancer (PID2604 V1.0)Paclitaxel 135 / Cisplatin 30 / Radiation, Cervical Carcinoma (PID1990 V1.1)Paclitaxel 175 / Carboplatin 5 followed by Radiation, Cervical Cancer adjuvant (PID97 V1.1)Paclitaxel 175 / Carboplatin 5, Cervical Cancer (PID1937 V1.0)Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer (PID600 V1.4)Paclitaxel 175 / Topotecan 0.75 / Bevacizumab 15, Cervical Cancer (PID769 V2.1)Paclitaxel 80 / Carboplatin 2, Cervical Cancer, Induction (PID2748 V1.0)Pembrolizumab 200 / Bevacizumab 15, Cervical Cancer, Cycle 7+ (PID2251 V1.1)Pembrolizumab 200 / Cisplatin 40 / Radiation, Cervical Cancer, Cycle 1-2 (PID2654 V1.0)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1890 V1.1)Pembrolizumab 200 / Paclitaxel 175 / Carboplatin 5, Cervical Cancer, Cycle 1-6 (PID1892 V1.1)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50 / Bevacizumab 15, Cervical Cancer, Cycle 1-6 (PID1891 V1.2)Pembrolizumab 200 / Paclitaxel 175 / Cisplatin 50, Cervical Cancer, cycle 1-6 (PID1900 V1.1)Pembrolizumab 200, Cervical Cancer (PID1331 V1.1)Pembrolizumab 200, Cervical Cancer, Cycle 3-5 (PID2655 V1.0)Pembrolizumab 200, Cervical Cancer, Cycle 7+ (PID1893 V1.1)Pembrolizumab 400, Cervical Cancer, Cycle 6-21 (PID2656 V1.0)Tisotumab Vedotin 2, Cervical Carcinoma (PID2002 V1.0)Topotecan 0.75 / Cisplatin 50, Cervical Cancer (PID1938 V1.1)
